Cell therapy for solid tumours is an innovative cancer treatment that uses a patient's own immune cells or donor cells to fight cancer, but its effectiveness varies by tumour type and patient's immune system. Although it offers new hope, it poses risks such as cytokine release syndrome and neurotoxicity. Recent advancements have led to better targeting, combination therapies, and next-generation treatments, with future research aimed at improving safety, effectiveness, and accessibility, potentially revolutionising cancer care.

The Food and Drug Administration (FDA) approved lifileucel, a one-of-a-kind T-cell therapy developed by Iovance Biotherapeutics for treating melanoma.

We caught up with Lindsay Davies, Chief Scientific Officer of NextCell Pharma, to hear about to hear about the latest advancements in stromal cell therapy in anticipation of her presentation at our Cell & Gene 2024 Congress this November.

Here, we speak to Marta Barisa, Senior Research Fellow at UCL, about switchable CAR-Ts and therapies for solid tumours.

Discover the transformative role of AI in the world of biotechnology. Dive deep into its synergy with 3D modeling, revealing groundbreaking advancements in cell & gene therapy and faster, more efficient drug development cycles.

Adaptimmune has developed from a strategic collaboration with GSK and embarked on a highly successful journey towards developing cancer immunotherapy treatments.

The biotech company BrainStorm is seeking regulatory approval from the FDA for its cell therapy, NurOwn, which has been developed for the treatment of ALS.